Abstract

Equine influenza virus (EIV) is a constantly evolving viral pathogen that is responsible for yearly outbreaks of respiratory disease in horses termed equine influenza (EI). There is currently no evidence of circulation of the original H7N7 strain of EIV worldwide; however, the EIV H3N8 strain, which was first isolated in the early 1960s, remains a major threat to most of the world’s horse populations. It can also infect dogs. The ability of EIV to constantly accumulate mutations in its antibody-binding sites enables it to evade host protective immunity, making it a successful viral pathogen. Clinical and virological protection against EIV is achieved by stimulation of strong cellular and humoral immunity in vaccinated horses. However, despite EI vaccine updates over the years, EIV remains relevant, because the protective effects of vaccines decay and permit subclinical infections that facilitate transmission into susceptible populations. In this review, we describe how the evolution of EIV drives repeated EI outbreaks even in horse populations with supposedly high vaccination coverage. Next, we discuss the approaches employed to develop efficacious EI vaccines for commercial use and the existing system for recommendations on updating vaccines based on available clinical and virological data to improve protective immunity in vaccinated horse populations. Understanding how EIV biology can be better harnessed to improve EI vaccines is central to controlling EI.

Highlights

  • Equine influenza virus (EIV) is a constantly evolving viral pathogen that is responsible for yearly outbreaks of respiratory disease in horses termed equine influenza (EI)

  • Murcia et al [80] suggested that increased vaccination in the 1980s intrasubtypic reassortment, of 13 distinguishable clades, the most recent 2 being the Florida clade 1 (FC-1) resulted in an EIV evolutionary bottleneck, which was broken by the emergence of Sufand Florida clade 2 (FC-2)

  • An inactivated whole virus EI vaccine consist of a whole EIV strain(s) that have been grown in mammalian culture or in the amniotic cavity of fertile hens’ eggs and denatured either by physical or chemical means

Read more

Summary

Recent Outbreaks of EIV

The transboundary transport of horses has allowed infectious disease pathogens to cross geographical barriers between nations of the world [1,2], enabling their spread to disease-free countries (Figure 1). The most recent outbreak of EIV across Europe was quite extensive, affecting 228 horse premises in the UK, 80 in Ireland, and 60 in France from the end of 2018 to 2019 according to the World Organization for Animal Health (OIE) report [27]. These outbreaks occurred among both vaccinated and unvaccinated horses, with reduced clinical manifestation observed in vaccinated horses, especially those with a history of appropriate and up-to-date vaccination over several years. Occasional outbreaks of EIV have been reported in South America in the past, there are pointers to a recent surge in the number of cases over the past few years [22]

Origin and mode of transmissionof of EIV: EIV
Evolution of EIV
Schematic
Schematic of evolution of EIV
EI Vaccines
Inactivated Whole Virus EI vaccines
Inactivated Whole Virus EI Vaccines
Subunit EI Vaccines
Recombinant Virus Vector Vaccines
DNA-Based EI Vaccines
10. EIV LAIVs Based on Truncations of the Viral NS1 Protein
12. Vaccine Efficacy Testing
13. Vaccine Updating
14. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call